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Abstract
Background: The Lactic Acid Bacteria (LAB) are important components of the healthy gut flora
and have been used extensively as probiotics. Understanding the cultivable diversity of LAB before
and after probiotic administration, and being able to track the fate of administered probiotic
isolates during feeding are important parameters to consider in the design of clinical trials to assess
probiotic efficacy. Several methods may be used to identify bacteria at the strain level, however,
PCR-based methods such as Random Amplified Polymorphic DNA (RAPD) are particularly suited
to rapid analysis. We examined the cultivable diversity of LAB in the human gut before and after
feeding with two Lactobacillus strains, and also tracked the fate of these two administered strains
using a RAPD technique.
Results: A RAPD typing scheme was developed to genetically type LAB isolates from a wide range
of species, and optimised for direct application to bacterial colony growth. A high-throughput
strategy for fingerprinting the cultivable diversity of human faeces was developed and used to
determine: (i) the initial cultivable LAB strain diversity in the human gut, and (ii) the fate of two
Lactobacillus strains (Lactobacillus salivarius NCIMB 30211 and Lactobacillus acidophilus NCIMB 30156)
contained within a capsule that was administered in a small-scale human feeding study. The L.
salivarius strain was not cultivated from the faeces of any of the 12 volunteers prior to capsule
administration, but appeared post-feeding in four. Strains matching the L. acidophilus NCIMB 30156
feeding strain were found in the faeces of three volunteers prior to consumption; after taking the
Lactobacillus capsule, 10 of the 12 volunteers were culture positive for this strain. The appearance
of both Lactobacillus strains during capsule consumption was statistically significant (p < 0.05).
Conclusion: We have shown that genetic strain typing of the cultivable human gut microbiota can
be evaluated using a high throughput RAPD technique based on single bacterial colonies. Validation
of this strategy paves the way for future systematic studies on the fate and efficacy of bacterial
probiotics during human clinical trials.
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Background
The application of bacterial probiotics or nutritional sup-
plements containing these microorganisms represents
one of the fastest growing areas in both industrial/clinical
microbiology. Probiotics have been defined by the World
Health Organisation live microorganisms which when
administered in adequate amounts, confer health benefits
on the host [1,2]. The Lactic Acid Bacteria (LAB; including
the genera Lactobacillus,  Enterococcus  and  Streptococcus)
comprise the most commonly used probiotics and have
been shown to have therapeutic or prophylactic potential
for a number of human and animal dietary conditions or
diseases [1,3,4]. The natural diversity of LAB in the human
gut has been studied by cultivation dependent methods
and conventional phenotypic identification of constitu-
ent species. More recently, powerful cultivation-inde-
pendent methods such as microbial metagenomics have
begun to shed light on the total microbial diversity of
human gut [5]. Although metagenomic studies allow
detailed analysis of what species of bacteria are present,
currently they provide only limited information on the
level of strain diversity that may occur for any given LAB
species.
Characterisation of the strain diversity of LAB species has
only really begun in the last decade. Yeung et al[6] suc-
cessfully used macrorestriction and Pulsed Field Gel Elec-
trophoresis (PFGE) to examine the genotypic diversity of
probiotic lactobacilli and showed that several commercial
probiotic formulations contained the same bacterial
strain. Vancanneyt et al. [7] used a combination of Ampli-
fied Fragment Length Polymorphism (AFLP) and PFGE to
specifically examine Lactobacillus rhamnosus species probi-
otics and also demonstrated the presence of multiple
indistinguishable strain types present in a variety of probi-
otic products. PCR-fingerprinting methods analysis have
also been used to examine the strain diversity of Lactoba-
cillus probiotics. For example, Schillinger et al. [8] used
Random Amplified Polymorphic DNA (RAPD) analysis to
differentiate Lactobacillus strains cultivated from probiotic
yogurts. Pena et al[9] used Repetitive Element PCR (REP)
profiling to examine the genetic diversity of intestinal
Lactobacillus  species colonising different transgenic
mouse-lines; they demonstrated that mice with colitis due
to IL-10 deficiency were colonised with a different popu-
lation of strains in comparison to those without colitis.
Multilocus sequence typing, a very powerful nucleotide
sequence based strain differentiation methods has also
been recently developed for Lactobacillus plantarum [10]
and Lactobacillus casei [11]. However, genetic typing meth-
ods that work at the strain level have seen limited use in
their direct application to the human gut microbiota and
have not yet been applied to specifically track the fate of a
specific probiotic strain during consumption.
Understanding the dynamics of gut colonisation by bacte-
rial probiotics is an important parameter for the future
clinical development of these therapeutic agents. We set
out to determine if individual Lactobacillus species strains
could be tracked after human consumption of the encap-
sulated bacteria. RAPD was selected as a suitable strain
typing method to answer this question because: (i) as a
PCR-based method it was amenable to high throughput,
and, (ii) we knew from past-experience that if the RAPD
method was systematically developed to target specific
bacterial species, then its discriminatory power can be
comparable to state-of-the-art DNA sequence-based geno-
typing methods such as multilocus sequence typing [12].
Here we describe the systematic development of a RAPD
fingerprinting method for a broad range of LAB species
and its optimization to allow direct application to single
bacterial colonies. Using this novel high throughput col-
ony strain typing strategy we were then able for the first
time to track the fate of specific Lactobacillus strains after
their consumption by human volunteers.
Results
Development of a RAPD fingerprinting method for Lactic 
Acid Bacteria
To systematically develop a RAPD typing scheme for LAB
species, a set of 100 RAPD primers which had proven suc-
cessful for strain typing other bacterial species [13,14]
were screened for their ability to amplify multiple poly-
morphisms from L. acidophilus. Fifteen primers (Table 1)
were found to reproducibly amplify 8 or more random
DNA fragments from the reference strain L. acidophilus
LMG 9433T that ranged in size from 200 to 4000 bp (Fig.
1). The complexity of these profiles indicated that dis-
criminatory typing of LAB isolates with these primers was
possible.
The primers with the most diverse polymorphisms, 272,
277 and 287 (Table 1; Fig. 1) were selected for genotyping
isolates of further LAB species beyond L. acidophilus. Pri-
mary typing was performed with primer 272 because of its
known discriminatory power [13,14], and secondary con-
firmation of strain type was performed with primers 277
and 287.
LAB isolates examined
A collection of 38 LAB isolates was assembled to assess the
discriminatory power of the RAPD fingerprinting method
(Table 2). The collection comprised reference isolates and
Type strains of known LAB species obtained from recog-
nised culture collections (14 isolates, 9 species; Table 2).
In addition, commercially marketed probiotic products
were purchased and their constituent LAB isolates cul-
tured and purified (24 isolates, 11 species; Table 2). Previ-
ous studies have shown that the speciation and labelling
of commercially marketed probiotics may often be inac-BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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curate [15,16]. Therefore prior to examining the ability of
RAPD to differentiate LAB isolates, sequence and phyloge-
netic analysis of the 16S rRNA gene was used to systemat-
ically identify the species of all LAB isolates cultured from
commercial samples (Fig. 2; Table 2). To test the accuracy
of this speciation strategy, control sequences from L. brevis
LMG 6906T and L. johnsonii LMG 9436Twere obtained and
found to cluster appropriately with the published
sequences from these Type strains (data not shown). The
majority of the cultivable bacteria contained within the
commercial probiotic products were found to belong to
the L. casei group (L. casei, L. paracasei and L. rhamnosus; 9
isolates) and L. acidophilus group (L. acidophilus, L. galli-
narum and L. suntoryeus species; 6 isolates) (Fig. 2; Table
2). Other LAB species identified included (Table 2): L. gas-
seri (3 isolates), L. jensenii (2 isolates), Enterococcus faecalis
(2 isolates), and L. salivarius, L. plantarum, and Pediococcus
pentosaceus (single isolates, respectively).
Testing the discriminatory power of the RAPD method on 
other LAB species
The broad collection of systematically identified LAB iso-
lates (Table 2) were used to test the efficacy of the RAPD
typing scheme. The reproducibility of the RAPD method
was excellent, with all 14 reference strains demonstrating
identical fingerprint profiles after duplicate analysis. In
addition L. acidophilus LMG 9433T was analysed by RAPD
at multiple points throughout the study as an internal
control; the same fingerprint profile was obtained on each
occasion demonstrating that the LAB PCR genotyping
scheme demonstrated the same high reproducibility as
had been observed with previous RAPD studies on other
bacterial species [13,14].
RAPD fingerprinting was able to cluster genetically identi-
cal strains as well as differentiate distinct strains within
closely related LAB species. For example, multiple isolates
of L. acidophilus were found to possess identical RAPD fin-
gerprints (using primer 272) to the type strain for the spe-
cies, LMG 9433T  (Fig. 3, panel A). These included 4
additional reference isolates that had originally been
recovered from diverse sources such as from rat and
human faeces, as well as 4 isolates used in the commercial
probiotic products (Table 2). All L. acidophilus isolates
were genotypically indistinguishable even when exam-
ined with additional RAPD primers 277 and 287. These
data suggested there was little genetic heterogeneity
among isolates of L. acidophilus examined in this study. In
addition they show that isolates genotypically identical to
the L. acidophilus Type strain have been widely adopted for
Table 1: Specifications of useful RAPD primers for typing Lactic Acid Bacteria
Primer name: Sequence (5' to 3') Approximate No. of polymorphisms from
L. acidophilus LMG 9433T
272 AGCGGGCCAA 13
277 AGGAAGGTGC 13
287 CGAACGGCGG 12
211 GAAGCGCGAT 11
275 CCGGGCAAGC 11
282 GGGAAAGCAG 11
244 CAGCCAACCG 10
245 CGCGTGCAAG 10
257 CGTCACCGTT 9
283 CGGCCACCGT 9
212 GCTGCGTGAC 8
214 CATGTGCTTG 8
228 GCTGGGCCGA 8
261 CTGGCGTGAC 8
262 CGCCCCCAGT 8BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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commercial use (Fig. 3, panel A; Table 2). Of the remain-
ing 8 LAB reference isolates examined, 8 distinct RAPD
strain types were found that corresponded to each LAB
species (Table 2).
RAPD fingerprinting was also able to differentiate geneti-
cally unique strain types within very closely related species
such as those within the L. casei group (Fig. 2); these
included L. casei, L. paracasei and L. rhamnosus (Fig. 3,
panel B). From this closely related complex of species (Fig.
2), a total of 9 distinct RAPD types (10, 11, 12, 16, 17, 18,
20, 21, and 27; Table 2) were identified. Two commer-
cially marketed probiotics were found to contain the same
strain of L. rhamnosus (isolates FMD T2 and MW, RAPD
type 10; Table 2). Another commercial probiotic formula-
tion contained an L. casei strain, designated BF T1, that
was identical by RAPD to the L. casei Type strain LMG
6904T (Table 2). Overall, the RAPD fingerprinting method
was highly effective, working on all 38 LAB isolates exam-
ined irrespective of their species and reproducibly defin-
ing 26 RAPD types within this diverse collection (Table 2).
Application of RAPD fingerprinting to single colonies
To facilitate high throughput typing that could be applied
to screening LAB isolates cultivated directly from human
faeces, we evaluated if the PCR-fingerprinting method
could be adapted for use on single bacteria colonies. Sin-
gle colonies were picked with a sterile plastic tip and rapid
boiling/cooling in a Chelex® resin extraction buffer used
to obtain DNA for PCR (see Methods). The RAPD finger-
prints obtained from colonies processed in this way were
identical to those produced from conventionally extracted
high molecular weight DNA (Fig. 4). However, it was
found that consistent profiles were only obtained if the
RAPD PCR was set up immediately after the boiling and
chilling cycles of the colony extraction procedure. The
amplified PCR fingerprints deteriorated after subsequent
frozen storage of the Chelex® resin extracted DNA. To
overcome this potential problem, we examined if pro-
longed frozen storage (-20°C) of the resuspended colony
in Chelex® resin prior to full extraction by boiling was pos-
sible. This procedure did not affect the quality of the
RAPD profiles (Fig. 4). The ability to fingerprint from fro-
zen stored colony material provided a high throughput
strategy that could be used to systematically screen the
multiple colony types isolated from human faeces as part
of a Lactobacillus strain feeding study (see below).
Lactobacillus species feeding study design
A small scale proof-of-principle human feeding study was
performed to evaluate if the colony-fingerprint strategy
could be used to track specific LAB strains from ingestion
as capsule recovery from faeces. A capsule for oral admin-
istration was formulated to commercial standards which
contained two Lactobacillus species isolates: L. salivarius
strain NCIMB 30211 (1.8 × 1010 colony forming units
[cfu] per capsule) and L. acidophilus strain NCIMB 30156
(5.6 × 109 mean cfu per capsule). Twelve volunteers par-
ticipated in a feeding study where the capsule was taken
daily for 14 days; faecal samples were provided on days
before, during and after consumption as described in the
Methods. The volunteers were not advised to change their
diets in any way other than to take the capsule once a day
with some food on each of the trial days. At each faecal
sampling point, LAB were plated as described below, enu-
merated and multiple colonies genotyped by RAPD.
Cultivation of LAB species from human faeces
Although MRS agar is a well established cultivation
medium for semi-selective culture of LAB species [17], we
found that several non-LAB species, in particular Gram
negative enteric bacteria were frequently encountered as
contaminants after plating of human faeces (data not
shown). To assist with selection of the Lactobacillus species
in the feeding study, we investigated whether the addition
of polymyxin B to MRS medium (MRS-P agar, see Meth-
ods) would increase the selectivity of this medium by act-
ing as a counter-selection against coliforms. Addition of
polymyxin B at a concentration of 120 units per ml of agar
did not inhibit the viability of any of reference LAB species
isolates (Table 2) or the two Lactobacillus strains incorpo-
rated into the capsule. However, MRS-P was highly effec-
tive at reducing the number of contaminating Gram
Useful RAPD primers producing diverse polymorphisms  from L. acidophilus Figure 1
Useful RAPD primers producing diverse polymor-
phisms from L. acidophilus. The fingerprint patterns gen-
erated from strain LMG 9433T are shown for 15 of the 
primers which were capable of amplifying diverse polymor-
phisms. The primer number is shown above each lane (the 
corresponding primer sequence is given in Table 2) and the 
size of relevant molecular markers (lane M) indicated in bp. 
The primers selected for typing of LAB are shown (*) with 
primer 272 being run in duplicate as a control and test.
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Table 2: Reference, probiotic and faecal LAB isolates examined or isolated during the study
Isolate name 
(partial 16S rRNA gene sequence 
Accession no.)
Species or 16S rRNA gene closest 
BLAST match 
(Accession no. of closest match)
Source or product from which 
isolate was cultivated
RAPD strain type
Reference isolates
LMG 11428 L. acidophilus Rat faeces 1
LMG 11430 L. acidophilus Human 1
LMG 11467 L. acidophilus Human 1
LMG 11469 L. acidophilus Rat intestine 1
LMG 8151 L. acidophilus Acidophilus milk 1
LMG 9433T L. acidophilus Human 1
LMG 6906T L. brevis Human faeces 9
LMG 6904T L. casei Cheese 10
LMG 6901T L. delbruecki subsp. bulgaricus Yogurt 13
LMG 9203T L. gasseri Human 14
LMG 9436T L. johnsonii Human blood 15
LMG 6907T L. plantarum Pickled cabbage 19
LMG 7955 (EF442275) L. paracasei subsp. paracasei -1 6
ATCC 29212 (EF442298) Enterococcus faecalis Human urine 26
Probiotic and commercial isolates
NCIMB 30156 (CulT2; EF442276) L. acidophilus (NCFM; CP000033) Cultech Ltd. 1
C21 (EF442277) L. acidophilus (NCFM; CP000033) Commerciala 1
C46 (EF442278) L. acidophilus (NCFM; CP000033) Commerciala 1
HBAP T1 (EF442279) L. acidophilus NCFM (CP000033) Commercial probioticb 1
C80 (EF442280) L. suntoryeus strain LH5 (AY675251) Commerciala 3
MO (EF442281) L. suntoryeus strain LH5 (AY675251) Commercial probioticb 3
BF T1 (EF442282) L. casei subsp. casei ATCC 393 (AY196978) Commercial probioticb 10
C48 (EF442283) L. paracasei subsp. paracasei DJ1 
(DQ462440)
Cultech Ltd. 11
C65 (EF442284) L. paracasei subsp. paracasei DJ1 
(DQ462440)
Commerciala 12BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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C79 (EF442285) L. paracasei subsp. paracasei DJ1 
(DQ462440)
Commerciala 18
C83 (EF442286) L. paracasei subsp. paracasei DJ1 
(DQ462440)
Commerciala 17
P7 T1 (EF442287) L. paracasei subsp. paracasei DJ1 
(DQ462440)
Commerciala 21
GG L. rhamnosus LR2 (AY675254) Commercial probioticb 27
FMD T2 (EF442288) L. rhamnosus LR2 (AY675254) Commercial probioticb 20
MW (EF442289) L. rhamnosus LR2 (AY675254) Commercial probioticb 20
C44 (EF442290) L. gasseri TSK V1-1 (AY190611) Cultech Ltd. 2
C71 (EF442291) L. gasseri TSK V1-1 (AY190611) Cultech Ltd. 7
SSMB (EF442292) L. gasseri TSK V1-1 (AY190611) Commercial probioticb 22
C66 (EF442293) L. jensenii KC36b (AF243159) Cultech Ltd. 5
C72 (EF442294) L. jensenii KC36b (AF243159) Cultech Ltd. 4
NCIMB 30211 (CulT1; EF442295) L. salivaruis subsp. salivarius UCC118 
(CP000233)
Commerciala 25
HBRA T1 (EF442296) L. plantarum strain WCFS1 (AY935261) Commercial probioticb 23
HBRA T3 (EF442297) Pediococcus pentosaceus ATCC 25745 
(CP000422)
Commercial probioticb 24
C22 (EF442299) Enterococcus faecalis NT-10 (EF183510) Cultech Ltd. 8
Faecal isolates from human probiotic feeding study
A+16-4a (EF442300) L. gasseri TSK V1-1 (AY190611) This study 28
A+28-3a (EF442301) L. rhamnosus LR2 (AY675254) This study 29
A+28-3b (EF442302) L. rhamnosus LR2 (AY675254) This study 29
B-14-1a (EF442303) Streptococcus salivarius ATCC 7073 
(AY188352)
This study 31
B-14-2a (EF442304) L. mucosae BJ18-2 (AY341550) This study 32
B-14-4a (EF442305) Streptococcus salivarius ATCC 7073 
(AY188352)
This study 33
B-14-4b (EF442306) Streptococcus salivarius ATCC 7073 
(AY188352)
This study 34
Table 2: Reference, probiotic and faecal LAB isolates examined or isolated during the study (Continued)BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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B0-3a (EF442307) Streptococcus salivarius ATCC 13419 
(M58839)
This study 30
C-14-4b (EF442308) Enterococcus faecalis ABPL 007 (DQ983196) This study 35
C+28-3a (EF442309) L. salivaruis subsp. salivarius UCC118 
(CP000233)
This study 36
F-14-3a (EF442310) Enterococcus gallinarum F02025 (DQ465366) This study 38
G-14-1a (EF44211) Staphylococcus lugdunensis ATCC 43809 
(AB009941)
This study 40
G0-2a (EF44212) Enterococcus sanguinicola BAA-781 This study 39
P-14-2a (EF44213) Enterococcus gallinarum F02025 (DQ465366) This study 43
P0-1a (EF44214) L. rhamnosus LR2 (AY675254) This study 41
P0-1b (EF44215) L. rhamnosus LR2 (AY675254) This study 41
P0-2a (EF44216) Staphylococcus sp. CNJ924 PL04 
(DQ448767)
This study 42
P+28-2a (EF44217) Staphylococcus warneri PB1 (AY186059) This study 44
Q-14-2a (EF44218) L. paracasei subsp. paracasei DJ1 
(DQ462440)
This study 47
Q-14-4a (EF44219) Streptococcus salivarius clone (AM157451) This study 48
Q0-1a (EF44220) Enterococcus faecalis ABPL 007 (DQ983196) This study 45
Q0-4a (EF44221) Staphylococcus sp. CNJ924 PL04 
(DQ448767)
This study 46
Q+28-2a (EF44222) Streptococcus sp. clone (EF151147) This study 49
R-14-4a (EF44223) Enterococcus faecalis ABPL 007 (DQ983196) This study 51
R-14-5a (EF44224) Enterococcus faecalis ABPL 007 (DQ983196) This study 52
R0-1b (EF44225) Weissella cibaria ACA-DC 3411t2 
(AJ422031)
This study 50
S-14-2a (EF44226) L. fermentum strain L18 (DQ523484) This study 53
T+28-1a (EF44227) L. rhamnosus LR2 (AY675254) This study 41
T+28-4b (EF44228) Streptococcus agalactiae A909 (CP000114) This study 54
a Strain widely used in commercial applications however specific original source was not known
b Strain cultivated from a commercially marketed probiotic formulation
Table 2: Reference, probiotic and faecal LAB isolates examined or isolated during the study (Continued)BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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Phylogenetic distribution of LAB probiotics and bacteria cultivated during the feeding study Figure 2
Phylogenetic distribution of LAB probiotics and bacteria cultivated during the feeding study. A phylogenetic tree 
of aligned 16S rRNA genes from representative Lactobacillus reference strains, commercial probiotic strains and dominant iso-
lates recovered during the feeding trial is shown. Probiotic strains are shown in bold font and isolates from the feeding study 
are highlighted by the grey boxes. The tree was rooted with the 16S rRNA gene from Staphylococcus warneri ATCC 27836 and 
the genetic distance scale and bootstrap values indicated.
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negative enteric colonies seen after plating of human fae-
ces.
To examine the efficacy of the semi-selective MRS-P devel-
oped for enrichment of the LAB species within faeces, 29
of the most dominant cultivable isolates recovered from
10 of the volunteers at days -14, 0 and 28 (before and after
Lactobacillus feeding) were randomly selected for molecu-
lar identification. Using 16S rRNA gene sequence analysis
these dominant isolates were identified as (Table 2; Fig 2):
Lactobacillus species (10 isolates), Streptococcus species (7
isolates), Enterococcus species (7 isolates), Weissella species
(1 isolate) and Staphylococcus species (4 isolates). The lat-
ter Staphylococcus isolates were the only non-LAB species
isolated in high numbers on MRS-P agar after faecal plat-
ing. These data indicated that the MRS-P agar was effective
for selection of LAB species after faecal culture.
Tracking Lactobacillus strains after oral administration
RAPD fingerprinting of the major colony morphotypes
appearing after cultivation of each faecal sample was used
to determine if the Lactobacillus strains had survived gas-
tric and intestinal passage (Fig. 5). The mean faecal LAB
count was 8.8 ± 2.7 × 106 cfu per g faeces when all volun-
teer samples were analysed; consumption of the lactoba-
cilli did not significantly alter the total faecal LAB counts
obtained from any of the volunteers (data not shown).
Prior to the start of the study, L. salivarius strain NCIMB
30211, was not detected in any of the volunteers, how-
ever, strains matching L. acidophilus NCIMB 30156 were
cultivated from three of the volunteers at the pre-feeding
stage (Table 3). The appearance of this L. acidophilus
(RAPD strain type 1; Table 2) at this point in the study was
not unreasonable since it appeared to be a strain com-
monly found in food/probiotic products which may have
been consumed by the volunteers (Table 2).
After consumption of the capsule, the L. salivarius NCIMB
30211 strain was detected on day 2 in three volunteers (B,
G and S), on day 7 in two volunteers (F, see Fig. 5; S), with
only volunteer S remaining faeces positive for this strain
on days 21 and 28 (7 and 14 days, respectively, after feed-
ing stopped; Table 3). Increased detection of the L. acido-
philus NCIMB 30156 strain was also seen with 10 of the
volunteers culture positive for this strain at one or more
sample points during the feeding period (volunteers A-C,
F, G, J, N, P, R and S), and 3 of these (A, N, and S)
remained positive on days 21 and 28 (Table 3). L. salivar-
ius NCIMB 30211 was never the dominant cultivable LAB
Discrimination of LAB by RAPD typing Figure 3
Discrimination of LAB by RAPD typing. The ability of 
PCR fingerprinting (with primer 272) to cluster identical iso-
lates (Panel A) and differentiate distinct isolates within the L. 
casei group (Panel B) is shown. Strains shown in each lane are 
as follows: Panel A; 1, L. acidophilus LMG 9433T; lanes 2 to 6, 
matching L. acidophilus isolates LMG 11428, LMG 11430, C21, 
C46 and NCIMB 30211, respectively; Panel B; lanes 7 to 11, 
L. paracasei subsp paracasei isolates C48, C65, C83, C79 and 
LMG 7955, respectively; 12, L. casei LMG 6904 T; and 13, L. 
rhamnosus MW. Molecular size markers were run in lane M 
and the size of relevant bands is indicated; panel A and B rep-
resent composite lanes taken from a single gel in each case.
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Reproducibility of single colony RAPD fingerprints Figure 4
Reproducibility of single colony RAPD fingerprints. 
The polymorphismsamplified by primer 272 from conven-
tionally extracted DNA compared to single colony Chelex® 
extracted DNA are shown for two LAB strains as follows: 
lane 1, L. rhamnosus strain MW standard DNA extraction; 
lanes 2 to 4, single colonies of strain MW that were picked 
into Chelex® resin, stored frozen and then extracted imme-
diately prior to PCR; lane 5, L. acidophilus strain LMG 8151 
standard DNA extraction; lanes 6 to 8, single colonies of 
strain LMG 8151 that were processed with Chelex® as 
described. The size of relevant molecular size markers (lane 
M) are shown in bp.
M     1      2      3      4     5      6      7     8
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Table 3: Detection of Lactobacillus capsule strains and other faecal bacteria during the feeding study
Volunteer Detection of strain in faecal samples before and after consumption of the Lactobacillus 
capsulea
Other recurrent 
strainsb
(strains listed in 
Table 2)
L. salivarius NCIMB 30211 L. acidophilus NCIMB 30156
Before After Before After
Ac - - - + (D7,21,28) 5 strains (L. rhamnosus 
A+28)
Bd - + (D2) - + (D2) 2 strains (S. salivarius 
B0-3a)
C - - + (D-14) + (D16) 5 strains (E. faecalis C-14-
4b; L. salivarius C+28-3a)
Fe - + (D7) - + (D7) 1 strain (E. gallinarum 
F-14-3a)
G - + (D2) - + (D2) 4 strains (S. lugdenensis 
G-14-1a; E. sanguinicola 
G0-2a)
Jf - - - + (D12) 3 strains
N - - + (D-14, 0) + (D2,21,28) 2 strains (L. acidophilus 
NCIMB 30211)
P - - - + (D7) 6 strains (L. rhamnosus P0-
1a/n; E. gallinarum P-14-2a; 
Staphylococcus sp P0-2a; S. 
warneri P+28-2a)
Q - - - - 6 strains (E. faecalis Q0-1a; 
Staphylococcus sp Q0-4a; 
Streptococcus sp Q+28-2a)
Rg - - + (D-14) + (D8) 5 strains (E. faecalis R-14-
4a and R-14-5a; W. cibaria 
R0-1b)
S - + (D2,7,21, 28) - + (D7,21,28) 5 strains (L. fermentum 
S-14-2a)
T - - - - 3 strains (L. rhamnosus 
T+28-1a; S. agalactiae 
T+28-4b)
a D = day of faecal sample
b Recurrent strains cultivated from faecal sample provided at two or more time points
c Day +14 sample from this volunteer was provided on day 16
d Volunteer withdrew from the study on day 2
e Volunteer withdrew from the study on day 7
f Volunteer withdrew from the study on day 12
g Volunteer withdrew from the study on day 8BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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strain and was detected at 102 to 104 per g faeces (Fig. 5).
In contrast, L. acidophilus NCIMB 30156 was the most
dominant colony morphotype in volunteers A (day 7 and
28), B (day 2), F (day 7; see Fig. 5) and N (day 2, 21 and
28; Table 3), where it represented 38% or greater of the
total LAB count. The mean LAB count for these volunteers
at these time points was 1.8 ± 7.6 × 107 per g faeces indi-
cating that L. acidophilus NCIMB 30156 must have been
present at a level of at least 107 per g of faeces.
Statistical evaluation of Lactobacillus feeding in terms of
gut colonisation was carried out assuming a null hypoth-
esis that: "Consumption will lead to the subsequent detec-
tion by cultivation of the constituent strains within the
capsule in the faeces of each subject." Chi Squared analy-
sis demonstrated that the distribution of L. salivarius
NCIMB 30211 was significant, with none of the volun-
teers being positive prior to feeding, and 4 being culture
positive (B, F, G and S; Table 3) at least once during the
feeding period of the trial (Chi square = 4.8; p < 0.05). The
distribution of L. acidophilus strain NCIMB 30156 was also
significant (3 positive prior to feeding and 10 culture pos-
itive during feeding, Table 3; Chi square = 8.2, p < 0.01),
suggesting that consumption of the organism had led to a
significant increase in gut carriage of this L. acidophilus
strain. However, limited persistence of the strains was
observed in the culture positive volunteers after feeding
ceased. For L. acidophilus NCIMB 30156, 10 volunteers
were culture positive at least once during the feeding
period, this fell to 3 who were still positive on day 21 and
28 (Table 3). With L. salivarius NCIMB 30211 only volun-
teer S retained the strain in faeces at day 21 and 28 after
consumption had ceased (Table 3).
Specific LAB strains persist in individual humans
Although the persistence of the administered Lactobacillus
strains was not substantial after feeding had stopped,
other faecal LAB strains were recurrently cultivated at two
or more time points from all 12 volunteers (Table 3). The
RAPD fingerprinting strategy was able to detect the per-
sistence of these strains within the faeces for greater than
28 days in several of the volunteers (Fig. 6). Reproducible
fingerprints were obtained for Lactobacillus species, Strep-
tococcus species, Enterococcus species, and Weissella species
isolates that all persisted in this way (Table 2 and 3; Fig. 2
and 6). Several strains were also the dominant cultivable
isolates recovered from the faeces of certain volunteers,
suggesting that they were colonising that individual's gut.
For example, the Enterococcus sanguinicola strain (RAPD
type 39, representative isolate G-02-a, Table 2; Fig. 2)
recovered from volunteer G was first isolated at 14 days
prior to commencing the feeding study and the same
strain was also cultivated from their faeces at each subse-
quent sampling point until day 21 (see Fig. 6 for day 0 and
day 21 RAPD fingerprints). At the -14 day sampling point
this enterococcal strain was estimated to represent 1% of
the cultivable diversity (1.8 × 104 cfu per g faeces), how-
ever, within day 0 and day 6 samples it represented 99%
Detection of L. salivarius and L. acidophilus strains after feeding Figure 5
Detection of L. salivarius and L. acidophilus strains after feeding. The colony growth after plating of the day 7 faecal 
sample from volunteer F are show for the neat and third serial dilutions on MRS-P agar (panels A and B, respectively). Colonies 
picked for PCR fingerprinting are shown by the numbered arrows. The subsequent RAPD typing analysis is shown in panel C 
with the lane numbers corresponding to the colony numbers. Other lanes for panel C are as follows: M, molecular size mark-
ers (size in bp indicated); 1, L. salivarius NCIMB 30211 control and 2, L. acidophilus NCIMB 30156 control.
(A)
(B)
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of the observed growth (approximately 1.75 × 105 cfu per
g faeces); at day 21 it still represented 88% of the cultiva-
ble diversity, however, on day 28 it was not detected.
All the volunteers were colonised with persistent LAB
strains (specific to each individual) that represented
greater than 1% of their viable faecal growth; at least one
of these strains was identified to the species level for each
volunteer except J (Table 3). Apart from sharing of the L.
salivarius NCIMB 30211 and L. acidophilus NCIMB 30156
strains present within the administered feeding capsule,
only one other strain was detected in two volunteers, the
L. rhamnosus RAPD type 41 strain (Table 2). This L. rham-
nosus strain was shared by individuals P and T (Table 2
and Table 3). Overall, these results demonstrate the ability
of the fingerprinting strategy to detect and track the popu-
lation biology of cultivable faecal strains representative of
a broad range of LAB species.
Discussion
We successfully developed a rapid, colony-based strain
typing strategy that was able to track two Lactobacillus
strains from feeding via a capsule through to faecal dis-
charge in human volunteers. The RAPD typing system was
capable of genotyping a wide variety of LAB species and its
efficacy on single colonies provided a means to rapidly
discriminate LAB isolates cultivated from human faeces.
Evidence for survival and growth of the L. salivarius strain
was most convincing as it was not detected in any of vol-
unteers prior to the feeding study (Table 3). In contrast,
the L. acidophilus strain used in the capsule represented a
very common genotype used in commercial applications
(Table 2). Hence the appearance of L. acidophilus isolates
which matched the feeding strain NCIMB 30156 may
have been less attributable to consumption of the capsule.
However, statistical analysis demonstrated that the distri-
bution of L. acidophilus NCIMB 30156 after the feeding
trial was significant in terms of the number of positive vol-
unteers and in the majority of these positive individuals it
was the dominant cultivable LAB strain in faeces.
As far as we are aware, previous studies evaluating the
dynamics of LAB consumption by humans have not
examined the cultivable faecal diversity at the strain level.
Several studies have used cultivation-independent meth-
ods such as real-time PCR to quantify the DNA from pro-
biotic strains present in faeces by extrapolating this
amplification data to estimate of the numbers of bacteria.
Bartosch et al. [18] used real-time PCR to estimate the
total numbers of Bifidobacterium species present in the fae-
ces of elderly people taking a probiotic containing two
Bifidobacterium strains and an inulin-based prebiotic. They
demonstrated that probiotic consumption increased the
overall size of Bifidobacterium population in their subjects
as estimated by increase yields in the species-specific PCR
and also used cultivation-based approaches to show that
more LAB species were present in the probiotic consum-
ing subjects.
Maruo et al. [19] used RAPD to identify a strain-specific
marker for the probiotic strain Lactobacillus lactis subsp.
cremoris FC, and used real-time PCR to detect the strain's
DNA within the faeces of human subjects taking the pro-
biotic. They were able to show that the strain's DNA per-
sisted during probiotic administration suggesting that
between 105 and 109 bacterial cells were present per g of
faeces. However, no cultivation and detection of the L. lac-
tis subsp. cremoris strain FC was performed on the faecal
samples [19] to indicate that the strain remained viable
and actively colonised the gut during probiotic adminis-
tration. Real-time PCR is a highly sensitive method, how-
ever, its dependence on detecting DNA and the fact that
minute traces of DNA may take longer than cells to be
completely cleared from the digestive tract, means that the
method can be misleading in terms of providing func-
tional information on the viability and persistence of an
administered probiotic.
We have also shown that many commercial marketed pro-
biotic products contain the same LAB strain (Table 2).
Our RAPD typing was able to cluster genetically identical
Recurrent LAB strains carried by the human volunteers Figure 6
Recurrent LAB strains carried by the human volun-
teers. Several different strains of LAB were cultivated at sev-
eral sampling points during the Lactobacillus feeding trial. 
RAPD fingerprints of these persistent strains are shown for 
the following in each lane: 1, L. rhamnosus A+7-5a; 2, A+28-
3b*; 3, E. sanguinicola G0-2a*; 4, G0-2b; 5, G+21-1a; 6, E. fae-
calis Q0-1a; 7, Q0-1b; 8, Q+28-1a, 9, Q+28-1b; 10, L. rham-
nosus T0-2a; 11, T+23-1a; 12, T+28-1b (systematic 
identification for the latter strains shown in Table 2). Molecu-
lar size markers are shown in lane M (size in bp indicated) 
and the figure is a composite of lanes drawn from 8 gels.
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strains such as the multiple isolates matching the L. acido-
philus Type strain (LMG 9433T; RAPD type 1), L. casei Type
strain (LMG 6904T; RAPD type 10) and commonly used L.
rhamnosus strains (MW and FMD T2; RAPD type 20). Stud-
ies by Yeung et al. [6] and Vancanneyt et al. [7] have also
shown that multiple probiotic products often contain
common LAB strain types. The fingerprinting method was
also highly discriminatory distinguishing closely related
taxa within the L. casei group (Fig. 2), yet at the strain level
detecting 9 types among the 11 isolates examined from
this group. The RAPD PCR-fingerprinting method also
proved very robust and reproducible, with reference
strains and cultivated faecal strains producing exactly the
same amplified polymorphisms at widely disparate sam-
pling and analysis points (see Fig. 2 and Fig. 6). This
reproducibility and the amenability of PCR-fingerprinting
to high throughput analysis enabled it to be used to exam-
ine the molecular epidemiology of Lactobacillus consump-
tion by humans for the first time.
Our analysis demonstrated that for the Lactobacillus strains
administered in the feeding study, long term persistence
after consumption was not observed. Interestingly, per-
sistence for greater than 21 days was only observed in vol-
unteer S, the oldest subject in the study (age 65), from
which the L. salivarius NCIMB 30211 capsule strain was
recovered up to day 28 of the study. Increased probiotic
colonisation in older people has been observed by others
[18] and it will be intriguing to examine this phenome-
non further using the colony fingerprinting method. The
persistence seen with the subject-specific LAB strains cul-
tivated from faeces is also interesting in this regard. Com-
mercialisation of LAB strains for probiotic use is
dependent on a number of factors, however, from our
study and other work, it appears that many commercial-
ised LAB strains are genotypically identical to reference
strains deposited in recognised culture collections (Table
2). The fingerprinting strategy described herein could be
used to select LAB strains with better persistence in human
populations by screening a large population of healthy
people, and selecting the dominant LAB strain types for
evaluation as probiotics.
Conclusion
We have shown that specific Lactobacillus  strains con-
sumed as part of a feeding study can be tracked through
gastrointestinal passage via a colony-based strain typing
strategy. The ability to identify specific LAB strains in fae-
ces after human consumption provides a means to answer
many important questions concerning the clinical use of
probiotics. Our fingerprinting strategy could be used to
identify the presence of the LAB isolates of the same gen-
otype as potential probiotics prior to their administration
in clinical trials, therefore allowing outcome measures
dependent on the probiotic to be distinguished from
those dependent on individuals which may naturally
carry the same LAB strain. Overall, the successful applica-
tion of molecular epidemiological techniques to cultiva-
ble bacterial populations within the human gut provides
a platform for future systematic studies on the develop-
ment of probiotics, as well as a rapid means to assess the
strain diversity in healthy versus diseased humans.
Methods
Bacterial strains and cultivation
Lactobacillus reference strains were obtained from the Bel-
gium Coordinated Collections of Microorganisms
(BCCM; http://bccm.belspo.be/). Additional commercial
LAB isolates were obtained from Cultech Ltd (Port Talbot,
Wales, UK) or cultured directly from commercially mar-
keted probiotic products as described below; a list of the
strains used in this study is shown in Table 2. All strains of
LAB were cultivated on MRS agar or in MRS broth (Oxoid,
Basingstoke, UK) for 24 to 72 hours at 37°C. Commercial
probiotic capsules and powders were resuspended in 5 ml
MRS broth and serial dilutions plated onto MRS agar. To
improve the isolation of LAB species from faecal samples,
the semi-selective capacity of MRS agar was enhanced by
the additional of 120 units per ml of Polymixin B (MRS-P
medium; Polymixin B from, Sigma-Aldrich, Gillingham,
UK). Fresh growth of purified faecal isolates was swabbed
and resuspended in MRS broth containing 8% vol/vol
dimethylsulphoxide prior to storage at -80°C. Frozen
strains were revived by swabbing the surface of the frozen
resuspension and plating onto MRS agar followed by
incubation as above.
RAPD PCR fingerprinting
For standard RAPD fingerprinting, DNA was extracted
from 5 ml overnight broth cultures of LAB as previously
described [13]. For the rapid fingerprinting protocol,
preparation of DNA from single colonies was carried out
as follows. A sterile 200 μl plastic pipette tip was inserted
into a single freshly grown (no longer that 72 hours of
plate growth) bacterial colony, resuspended into 50 μl of
sterile 5% Chelex® 100 resin solution (Sigma-Aldrich, Gill-
ingham, UK), and then plated onto MRS agar to provide a
pure reference culture. The DNA extraction tubes were
stored frozen at -20°C prior to the extraction of DNA for
PCR. After thawing, the samples were boiled for 5 min
and immediately placed on ice for a further 5 min; this
heating and cooling cycle was repeated once to extract
DNA. The resin was removed by brief centrifugation and
2 μl of the clear supernatant DNA solution used for the
RAPD PCR.
PCR fingerprinting was carried out using a procedure that
was modified from that described [13]. RAPD primers 201
to 300 (10 μg aliquots) were purchased from the Nucleic
Acid Protein Service Unit at the University of BritishBMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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Columbia, Vancouver, Canada http://www.michaels
mith.ubc.ca/services/NAPS/. The primers that were found
to be appropriate for LAB typing (272, 277 and 287; Table
1) were subsequently ordered individually in bulk from
MWG Biotech (Covent Garden, London), dissolved as
stocks in water at 100 pmol/μl and stored frozen. All PCR
reagents were purchased from Qiagen Ltd. (Crawley, UK)
and routine fingerprinting was carried out in a 25 μl reac-
tion mixture containing: 2.5 μl PCR buffer, 5 μl Q-solu-
tion, 1.5 μl 25 mM MgCl2 (3 mM final concentration), 0.5
μl 10 mM dNTPs mixture (200 μM final concentration), 4
μl of 10 pmol/μl stock of RAPD primer, 2 μl of template
DNA (approximately 40 ng) and 0.2 μl (1 unit) of Taq
DNA polymerase. The PCR thermal cycles were carried out
on a Flexigene Thermal Cycler (Techne Ltd., Newcastle,
United Kingdom) as follows (ramping time between tem-
peratures): (i) 4 cycles of 94°C for 5 min., 36°C for 5 min.
(70 sec. cooling time), and 72°C for 5 min. (70 sec. heat-
ing time), (ii) 30 cycles of 94°C for1 min. (55 sec. to heat
from 72°C), 36°C for 1 min. (60 sec to cool), 72°C for 2
min. (70 sec. to heat); and (iii) a final extension of 72°C
for 6 min. followed by a hold at 4°C indefinitely.
All reference LAB strains (Table 2) were typed in duplicate
and the type strain L. acidophilus LMG 9433T was also used
as an internal reproducibility control throughout all
RAPD analysis, with multiple repeats performed to ensure
RAPD typing was reproducible. Fingerprint profiles were
separated by standard gel electrophoresis [13] using 1.5%
high resolution agarose gels (Sigma-Aldrich, Poole UK).
RAPD fingerprints were analysed using computer software
(Gel Compar II, Appied Maths, Sint-Martens-Latem, Bel-
gium) and fingerprint profiles compared by calculation of
the Dice coefficient and clustering using the unweighted
pair-group method average (UPGMA); isolates with
RAPD fingerprint Dice coefficients greater than 0.85 were
designated as a distinct bacterial strain.
Molecular systematics
The 16S rRNA gene was used as the primary means to
identify LAB isolates and other bacteria isolated during
the feeding study. The primers applied by Yeung et al. [16]
PAF, 5'-AGA GTT TGA TCC TGG CTC AG-3' and 536-R, 5'-
GTA TTA CCG CGG CTG CTG-3', were used to amplify a
528 bp portion of the 16S rRNA gene. The resulting PCR
product was sequenced on both strands using the latter
primers and Applied Biosystems Big Dye Terminator
ready reaction mix version 3.1, with subsequent analysis
on an Applied Biosystems ABI-Prism 3100 automated
sequencer. The end sequence reads were aligned, error
checked and trimmed to 500 nucleotides to produce a
consensus sequences using BioEdit [20]. Sequences were
compared to: (i) the Ribosomal Database Project II (RDP
II; http://rdp.cme.msu.edu/) using the sequence match
tool, and (ii) GenBank using the Basic Local Alignment
Search Tool (BLAST) at the National Centre for Biotech-
nological Information (NCBI; http://
www.ncbi.nlm.nih.gov/), to facilitate identification.
To further enable accurate speciation within the genus
Lactobacillus, 116 full-length 16S rRNA genes for reference
isolates and type strains within this group were down-
loaded from the RDP II site and trimmed to match the 500
nucleotide portion obtained from isolates as above. The
sequences were aligned using CLUSTAL W [21] and ana-
lysed phylogenetically using MEGA 3.1. Several tree-con-
struction algorithms were evaluated; genetic distance trees
drawn using the Jukes-Cantor neighbour-joining method
were selected for the study because they produced phylog-
enies that were congruent with the current LAB taxonomy
of LAB. To confirm identification of novel non-Lactobacil-
lus species isolated during the study, 16S rRNA genes from
their closest RDP II match (species Type strains) were
included in the phylogenetic analysis. A total of 54 partial
16S rRNA gene sequences were determined as part of this
study and have been deposited in GenBank (Accession
numbers are shown in Table 2).
Lactobacillus feeding study
A probiotic-like capsule (manufactured by Cultech Ltd,
Port Talbot, UK) containing the following strains was for-
mulated according to standard food product guidelines: L.
salivarius strain NCIMB 30211 and L. acidophilus strain
NCIMB 30156. The two strains were selected merely on
the basis that each had been previously used in probiotic
formulations manufactured by Cultech Ltd. The probiotic
capsule was taken once a day for 14 days during feeding
study. Fifteen healthy volunteers were initially enrolled
and 12 participated in the final study. All volunteers gave
written consent to provide faecal samples and take the
Lactobacillus capsules as part of the feeding trial; all were
free to withdraw from the study at any point. In addition,
no exclusion criteria applied to the volunteers and they
were free to eat normally (including diary products) or
take medicinal drugs (such as antibiotics) at any point in
the study.
Faecal samples were provided as follows: (i) Day -14, 2
weeks prior to commencing probiotic administration as a
pre-study control; (ii) Day 0, the start day for probiotic
feeding with the fecal sample taken before ingestion of the
first capsule; (iii) Day 2; (iv) Day 7; (v) Day 14 as the last
day the probiotic formulation was taken; (vi) Day 21, 21
days after probiotic consumption and 7 days following
cessation of feeding; and finally (vi) Day 28, 28 days after
first probiotic consumption and 14 days following cessa-
tion of probiotic administration. Ethical approval for the
feeding study was granted by Cardiff School of Bio-
sciences, Cardiff University (Approval number 079-1).BMC Microbiology 2009, 9:251 http://www.biomedcentral.com/1471-2180/9/251
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Cultivation of LAB from faecal samples
Fresh faecal samples were weighed, diluted 1:10 MRD
diluent (Oxoid, Basingstoke, UK) containing 15% glyc-
erol, and frozen at -80°C; no significant loss of cultivable
diversity or viability was observed when freshly resus-
pended and plated faecal samples were compared to rep-
licate samples that had been stored frozen. Serial dilutions
were plated in replicate onto MRS and MRS-P agar, incu-
bated at 37°C for 72 hours, and enumerated quantita-
tively and qualitatively prior to random picking of up to
10 the different colony morphotypes for RAPD finger-
printing. Each serial dilution plate was documented using
digital photography; if RAPD detected the presence of
either feeding study strain (L. salivarius strain NCIMB
30211 or L. acidophilus strain NCIMB 30156; see Fig. 6),
then retrospective counting of all the morphotypes associ-
ated with the strains was performed to determine a total
count per gram of faeces.
Statistical analysis
For enumeration of the faecal counts on MRS-P agar, the
mean and standard error of the mean were determined
and a 2-sample t-test to compare means (all numerical
analysis was performed using MINITAB® Release 15, Min-
itab Inc.). The overall results of the Lactobacillus feeding
study were analysed non-parametrically using Chi square
because of the limited number of subjects and the varia-
bles measured. A 2 × 2 data table was constructed for the
analysis categorising the data as follows: two columns for
the number of volunteers positive and negative for the
administered Lactobacillus  strains, respectively, and two
rows for before and after capsule consumption, respec-
tively (positive cultures for any given volunteer were only
counted once).
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